Vaxcyte Inc
PCVX
查看详细走势图
47.650USD
-0.160-0.33%
收盘 12/24, 16:00（美东）报价延迟15分钟
6.20B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.33%
5天
+9.01%
1月
-5.16%
6月
+44.00%
今年开始到现在
-41.79%
1年
-44.53%
查看详细走势图
TradingKey Vaxcyte Inc股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值合理，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
Vaxcyte Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
11
位分析师
买入
评级
98.000
目标均价
+112.21%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Vaxcyte Inc亮点
亮点风险
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值高估
公司最新PE估值-10.84，处于3年历史高位
机构减仓
最新机构持股152.55M股，环比减少6.28%
李·安斯利持仓
明星投资者李·安斯利持仓，最新持仓市值1.31M
Vaxcyte Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Vaxcyte Inc简介
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
公司代码PCVX
公司Vaxcyte Inc
CEOPickering (Grant E)
网址https://vaxcyte.com/
常见问题
Vaxcyte Inc(PCVX)的当前股价是多少？
Vaxcyte Inc(PCVX)的当前股价是 47.650。
Vaxcyte Inc的股票代码是什么？
Vaxcyte Inc的股票代码是PCVX。
Vaxcyte Inc股票的52周最高点是多少？
Vaxcyte Inc股票的52周最高点是93.770。
Vaxcyte Inc股票的52周最低点是多少？
Vaxcyte Inc股票的52周最低点是27.660。
Vaxcyte Inc的市值是多少？
Vaxcyte Inc的市值是6.20B。
Vaxcyte Inc的净利润是多少？
Vaxcyte Inc的净利润为-463.93M。
现在Vaxcyte Inc(PCVX)的股票是买入、持有还是卖出？
根据分析师评级，Vaxcyte Inc(PCVX)的总体评级为买入，目标价格为98.000。
Vaxcyte Inc(PCVX)股票的每股收益（EPS TTM）是多少
Vaxcyte Inc(PCVX)股票的每股收益（EPS TTM）是-4.848。
相关品种
